51. Novel Effective Medical Therapy for Acanthamoeba Keratitis.
- Author
-
Di Zazzo A, De Gregorio C, and Coassin M
- Subjects
- Adult, Female, Humans, Male, Antiprotozoal Agents therapeutic use, Benzamidines therapeutic use, Ophthalmic Solutions, Visual Acuity, Adolescent, Acanthamoeba Keratitis drug therapy, Biguanides therapeutic use
- Abstract
Purpose: To report first clinical use of novel medical treatment for Acanthamoeba keratitis., Methods: Interventional observational case series. Two patients with Acanthamoeba keratitis were unsuccessfully treated with polihexanide (PHMB) 0.02% and propamidine 0.1% for 6 weeks, then all were shifted in a compassionate use of PHMB 0.08% with novel standardized protocol. The postinterventional follow-up of patients was at least 7 months., Results: PHMB 0.08% eyedrops in a novel standardized protocol improved infection resolution and led to complete healing of the lesion after 4 weeks in the two cases. Corneal opacities and neovascularization decreased slowly, best-corrected visual acuity slightly improved and progressively increased in the further 7 months, and no infection recurrence occurred., Conclusions: This preliminary report of two cases shows promising response to polihexanide 0.08% lowering drastically the illness duration, with reduced chance of recurrence, and mostly improving patients' quality of life., Competing Interests: The authors have no conflict of interest to declare., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Contact Lens Association of Opthalmologists.)
- Published
- 2024
- Full Text
- View/download PDF